• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Circadian effects of scopolamine on memory, exploratory behavior, and muscarinic receptors in mouse brain.

作者信息

Pan S Y

机构信息

Department of Pharmacology, Beijing College of Traditional Chinese Medicine.

出版信息

Zhongguo Yao Li Xue Bao. 1992 Jul;13(4):323-6.

PMID:1456053
Abstract

Mice were maintained at light-dark cycle with lights on from 05:00-19:00 for 10 d in laboratory. The study was performed at 07:00-09:00, 15:00-17:00, and 21:00-23:00 in June and July. Scopolamine (Scop, 0.1 and 0.4 mg.kg-1, ip) was injected 15 min prior to training or the first exploratory test. The amnesic effects of Scop showed hyperresponses at 07:00-09:00 and 15:00-17:00, and hyporesponses at 21:00-23:00 using step-through and step-down tasks. The circadian effects of Scop on exploratory behavior were consistent with the findings above mentioned. The numbers of [3H]quinuclidinyl benzilate ([3H]QNB) binding sites in the temporal cortex and hippocampus were more at 08:00 and 16:00 than those at 22:00. However, muscarinic receptor levels in the striatum were lower at 08:00 than those at 22:00. These results indicated that the effects of Scop on memory, behavior in a novel environment, and muscarinic receptors in brain regions showed circadian changes in mice.

摘要

相似文献

1
Circadian effects of scopolamine on memory, exploratory behavior, and muscarinic receptors in mouse brain.
Zhongguo Yao Li Xue Bao. 1992 Jul;13(4):323-6.
2
Acetylcholine contents and muscarinic receptor levels in frontal cortex, corpus striatum, and hippocampus of reserpinized rats and mice.利血平化大鼠和小鼠额叶皮质、纹状体及海马中的乙酰胆碱含量和毒蕈碱受体水平。
Zhongguo Yao Li Xue Bao. 1992 May;13(3):223-6.
3
Manganese toxicity: muscarinic receptor binding in the mouse brain.锰毒性:小鼠大脑中的毒蕈碱受体结合
J Toxicol Environ Health. 1994 Jun;42(2):185-91. doi: 10.1080/15287399409531872.
4
Muscarinic receptor blockade in ventral hippocampus and prelimbic cortex impairs memory for socially transmitted food preference.腹侧海马体和前边缘皮层中的毒蕈碱受体阻断会损害对社会传递性食物偏好的记忆。
Hippocampus. 2009 May;19(5):446-55. doi: 10.1002/hipo.20530.
5
Comparative behavioral and neurochemical activities of cholinergic antagonists in rats.大鼠体内胆碱能拮抗剂的比较行为学和神经化学活性
J Pharmacol Exp Ther. 1993 Oct;267(1):16-24.
6
Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.N-乙氧羰基-2-乙氧基-1,2-二氢喹啉体内和体外处理对大鼠脑内假定毒蕈碱受体亚型的影响。
Mol Pharmacol. 1986 Aug;30(2):96-103.
7
Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice).关于促智药阿屈非尼、氯酯醒和吡拉西坦以及胞磷胆碱对东莨菪碱损害的记忆、探究行为和身体能力影响的比较研究(大鼠和小鼠实验)
Acta Physiol Pharmacol Bulg. 1988;14(1):3-13.
8
Supersensitivity of the cholinergic muscarinic system in the rat's brain is induced by high concentrations of Cu+2.高浓度的Cu+2会诱发大鼠大脑中胆碱能毒蕈碱系统的超敏反应。
Invest Clin. 2002 Jun;43(2):107-17.
9
Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.通过抑制[3H]哌仑西平和[3H]喹核醇基苯甲酸酯与大鼠脑膜的结合来研究加拉明与毒蕈碱M1和M2受体的结合。
Mol Pharmacol. 1986 Jul;30(1):58-68.
10
Acute and chronic effects of ethanol on receptor-mediated phosphatidylinositol 4,5-bisphosphate breakdown in mouse brain.乙醇对小鼠脑内受体介导的磷脂酰肌醇4,5-二磷酸水解的急性和慢性影响。
Mol Pharmacol. 1986 Jul;30(1):13-8.

引用本文的文献

1
Two Players in the Field: Hierarchical Model of Interaction between the Dopamine and Acetylcholine Signaling Systems in the Striatum.领域中的两个参与者:纹状体中多巴胺与乙酰胆碱信号系统相互作用的层次模型
Biomedicines. 2021 Jan 1;9(1):25. doi: 10.3390/biomedicines9010025.